CYTK
Cytokinetics Inc
67.60$
-1.8%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.6% | 98.2% | 93.2% | 93.0% | 98.3% | 80.7% | 88.8% | 63.7% | 78.4% | 76.2% | 79.0% | 64.4% | |
| 15.2% | 56.5% | 39.3% | 42.5% | 20.0% | 12.6% | 15.5% | 13.4% | 6.5% | 13.7% | 6.8% | 8.6% | |
| 62.6% | 96.7% | 91.8% | 91.2% | 94.1% | 77.7% | 86.9% | 56.1% | 77.1% | 74.6% | 76.8% | 61.9% | |
| 35.1% | 0.0% | 0.0% | 0.4% | 3.2% | 1.8% | 0.8% | 6.2% | 0.0% | 0.2% | 1.2% | 1.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | -3.2% | – | -0.8% | -6.2% | 0.0% | -1.4% | – | – | |
| 1.2% | 1.5% | 2.1% | 1.2% | 1.5% | 1.6% | 2.5% | 8.7% | 7.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 30.8% | 40.5% | 44.5% | 62.7% | 87.7% | 103.8% | 78.8% | 71.0% | 110.6% | 146.9% | 109.7% | 146.3% | |
| 17.9% | 27.5% | 19.5% | 11.0% | 10.5% | 9.0% | 5.8% | 8.5% | 8.3% | 12.5% | 12.8% | 14.2% | |
| 1.0% | 1.9% | 1.5% | 1.8% | 1.2% | 1.6% | 0.5% | 1.8% | 1.4% | 3.4% | 2.2% | 4.2% | |
| 1.0% | 1.9% | 2.5% | 1.8% | 1.8% | 2.8% | 1.5% | 2.5% | 2.5% | 2.6% | 1.5% | 1.6% | |
| 0.0% | 12.7% | 16.1% | 10.8% | 18.8% | 15.5% | 8.7% | 5.6% | 6.3% | 73.7% | 46.1% | 78.3% | |
| 69.2% | 59.5% | 55.5% | 37.3% | 12.3% | -3.8% | 21.2% | 29.0% | -10.6% | -46.9% | -9.7% | -46.3% | |
| -374.0% | -464.0% | -304.6% | -219.2% | -352.0% | -298.5% | -185.9% | -143.5% | -156.3% | -256.2% | -192.8% | -244.8% | |
| 26.9% | 33.7% | 25.0% | 16.8% | 25.8% | 19.9% | 12.1% | 9.1% | 8.9% | 11.7% | 8.0% | 8.4% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.